Genmab — November 2018
-
Evt. på mail [email protected].
-
-
Salget af Genmabs kræftmiddel Darzalex gik frem på det amerikanske marked i oktober.
Darzalex, der er godkendt til behandling af knoglemarvskræft, solgte for 127,5 mio. dollar i USA, hvilket var 11,5 pct. højere end i september, og lige over 40 pct. højere end i oktober sidste år.
-
det er godkendt
-
alt tyder på, at vi kommer i mål i år, og får en stor milestone i december
-
...buy the rumour... sell the fact...og godt nytår så

-
any comments on this tweet? https://twitter.com/JacobPlieth/status/1064960354516697088
-
-
why would You go against the best for the patients???
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
spnd